Results 171 to 180 of about 436,330 (367)

Efficacy and Safety of Janus Kinase Inhibitors in Type I Interferon-Mediated Monogenic Autoinflammatory Disorders: A Scoping Review

, 2021
Pedro Jesús Gómez‐Arias, Francisco Gómez‐García, Jorge Hernández-Parada, Ana Montilla-López, Juan Ruano, Esmeralda Parra-Peralbo   +5 more
openalex   +1 more source

Unravelling the Major Cardiovascular Risks of Systemic Psoriasis Medications: A Literature Systematic Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Psoriasis is a chronic inflammatory dermatological condition associated with an elevated risk of cardiovascular events (CVEs). Systemic therapies have transformed disease management, but their cardiovascular (CV) safety profiles remain incompletely understood and inconsistently reported.
Mai Thi Hoai Son, Yves Julien Mbama Biloa, Pauline Gouttefarde, Thomas Franck, Gilles Cizeron, Mathieu Oriol, François Maccari, Elisa Cinotti, Beatrice Trombert‐Paviot, Bienvenu Bongue, Jean‐Luc Perrot   +10 more
wiley   +1 more source

Janus Kinase Inhibitors in the Treatment of Crohn’s Disease and Ulcerative Colitis: A Review

Quality in Sport
Introduction and purpose: Insufficient efficacy and adverse effects of classical therapies for inflammatory bowel disease (IBD), such as ulcerative colitis and Crohn's disease, have prompted the search for new, more targeted treatment methods.
Olimpia Wiciun, Karolina Skonieczna, Kacper Ordon, Magdalena Badziąg, Paulina Szulc, Laura Kurczoba, Martyna Kłossowska, Olga Kądziołka   +7 more
doaj   +1 more source

Narrow spectrum kinase inhibitors demonstrate promise for the treatment of dry eye disease and other ocular inflammatory disorders [PDF]

, 2018
Doughty, Michael, Foster, Martyn R., Fyfe, Matthew C.T., Hagan, Suzanne, Ofori-Frimpong, Boatemaa, Oliver, Katherine, Rowley, Adele, Sirohi, Sameer, Solanke, Yemisi, Taylor, Mike, Walshe, Claire A., Webber, Steve   +11 more
core   +1 more source

Safety of Baricitinib for the Treatment of Atopic Dermatitis in Adults Over a Median of 1.6 and up to 4.6 Years Treatment: Final Integrated Analysis of Eight Clinical Trials

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Baricitinib is a selective Janus kinase (JAK)1/JAK2 inhibitor approved in more than 70 countries for the treatment of moderate‐to‐severe atopic dermatitis (AD) in adults, and in over 30 countries for adolescents and children from age 2 years with moderate‐to‐severe AD, who are candidates for systemic therapy.
Antonio Costanzo, Antonio Torrelo, Eric L. Simpson, Marjolein De Bruin‐Weller, Diamant Thaçi, Norito Katoh, Silvia Sabatino, Andrew Buchanan, Kasia Morawska, Samuel Ogwu, Karen Denning, Jonathan I. Silverberg   +11 more
wiley   +1 more source

Structure, function and inhibition of poly(ADP-ribose)polymerase, member 14 (PARP14) [PDF]

, 2018
Levonis, Stephan M, Schweiker, Stephanie S, Sherry, Madeleine, Tauber, Amanda   +3 more
core   +1 more source

P008 High response rate to Janus Kinase inhibitors after multiple biologic drug failures, across disease indications, in a District General Hospital: results from an audit of the prescribing, safety and efficacy of Janus Kinase inhibitor [PDF]

Alexa Escudero, Sugandh Jain, Nwe Nisoe, Jeremy McNally, Habib Wardak   +4 more
openalex   +1 more source

Suppressor of Cytokine Signaling 1–Derived Peptide Inhibits Janus Kinase/Signal Transducers and Activators of Transcription Pathway and Improves Inflammation and Atherosclerosis in Diabetic Mice [PDF]

, 2014
Carlota Recio, Ainhoa Oguiza, Iolanda Lázaro, Beñat Mallavia, Jesús Egido, Carmen Gómez‐Guerrero   +5 more
openalex   +1 more source

Characteristics of Adult Patients With Atopic Dermatitis Initiating Biologics and Janus Kinase Inhibitors in the CorEvitas Atopic Dermatitis Registry

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Biologics and Janus kinase inhibitors (JAKi) are two advanced systemic treatment options for patients with atopic dermatitis (AD). The decision to initiate one of these therapies is complex and may be driven by many factors.
Eric L. Simpson, Linda Stein Gold, Seemal R. Desai, Alexandra K. Golant, Douglas DiRuggiero, Christian Fenske, Yolanda Muñoz Maldonado, Alvin H. Li, Zach Dawson, Kaylee Ho, Kayla Callahan, Gaia Gallo, Jonathan I. Silverberg   +12 more
wiley   +1 more source

Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses

Frontiers in Immunology
Biologics play a positive and effective role in the treatment of immune-related dermatoses. However, many other immune-related diseases have also manifested along with biologics treatment.
Yaxin Zhang, Yaxin Zhang, Guan Jiang
doaj   +1 more source